Jianli Yang, Wenwei Shi, Hao Xie, Yuan Zhang, Jiaying Li, Gang Guo, Mengxuan Yuan, Zhenyu Zou, Xuetao Mu
3D-PCAR reflects prostate sphericity and correlates with symptom severity in BPH, demonstrating potential as a novel non-invasive imaging biomarker for evaluating intraprostatic pressure and urinary symptoms.
OBJECTIVES: To quantitatively assess morphological alterations in benign prostatic hyperplasia (BPH) using MRI-based three-dimensional presumed circular area ratio (3D-PCAR), and to explore its correlation with International Prostate Symptom Score (IPSS).
MATERIALS & METHODS: A total of 335 patients with pathologically confirmed BPH who underwent preoperative prostate MRI and completed IPSS questionnaire were retrospectively analyzed. MRI-derived volume parameters included total prostate volume (TPV), transition zone volume (TZV), and transition zone index (TZI, TZI = TZV / TPV); morphological parameters included intravesical prostatic protrusion (IPP), PCAR (axial, coronal, and sagittal), and peripheral zone thickness (PZ-thickness). Correlations between MRI-derived parameters and total IPSS, IPSS storage sub-score (IPSS-ss) and IPSS voiding sub-score (IPSS-vs) were analyzed using Pearson correlation, one-way analysis of variance (ANOVA) and multivariable regression.
RESULTS: All MRI parameters showed significant correlations with IPSS scores (all p < 0.05). Positive correlations with IPSS were observed for IPP, TPV, TZV, TZI, and PCAR (r = 0.18-0.59), whereas PZ-thickness showed negative correlations (r = - 0.18 to - 0.24). Among the evaluated MRI-derived parameters, PCAR measurements in all three planes demonstrated moderate-to-strong correlations with IPSS (axial r = 0.485, 0.474, 0.405; coronal r = 0.592, 0.553, 0.524; sagittal r = 0.545, 0.508, 0.484, all p < 0.001) and remained significant predictors of IPSS in multivariable analyses (p < 0.05).
CONCLUSION: 3D-PCAR reflects prostate sphericity and correlates with symptom severity in BPH, demonstrating potential as a novel non-invasive imaging biomarker for evaluating intraprostatic pressure and urinary symptoms.